MCID: ACT008
MIFTS: 49

Actinic Keratosis

Categories: Cancer diseases, Genetic diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Actinic Keratosis

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 11 75 53 14 16 71 31 33
Solar Keratosis 11 33
Ak - [actinic Keratosis] 33
Sk - [solar Keratosis] 33
Senile Hyperkeratosis 11
Seborrheic Keratosis 71
Sk - Solar Keratosis 11
Actinic Keratosis 11
Keratosis, Actinic 43

Classifications:



External Ids:

Disease Ontology 11 DOID:8866
ICD9CM 34 702.0
MeSH 43 D055623
NCIt 49 C3148
SNOMED-CT 68 267858008
ICD10 31 L57.0
ICD11 33 1803982621
UMLS 71 C0022602 C0022603

Summaries for Actinic Keratosis

MalaCards based summary: Actinic Keratosis, also known as solar keratosis, is related to keratosis and squamous cell carcinoma. An important gene associated with Actinic Keratosis is TP63 (Tumor Protein P63), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Toll-Like receptor Signaling Pathways. The drugs Bacitracin and Mineral oil have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and liver, and related phenotypes are endocrine/exocrine gland and neoplasm

Wikipedia: 75 Actinic keratosis (AK), sometimes called solar keratosis or senile keratosis, is a pre-cancerous area of... more...

Related Diseases for Actinic Keratosis

Diseases in the Actinic Keratosis family:

Keratosis, Familial Actinic

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 420)
# Related Disease Score Top Affiliating Genes
1 keratosis 32.6 TP53 MC1R KRT10 FLG CDKN2A BCL2
2 squamous cell carcinoma 31.9 TP63 TP53 MKI67 CDKN2A BCL2
3 skin squamous cell carcinoma 31.8 TP53 KRT10 KNSTRN CDKN2A
4 bowen's disease 31.7 PCNA MKI67 KRT10
5 skin carcinoma 31.4 VDR TP53 TNF TLR7 MC1R H2AC18
6 keratosis, seborrheic 31.1 TP53 MC1R KRT10 CDKN2A
7 cheilitis 31.0 TP53 TNF BCL2
8 common cold 30.9 TNF IFNA1 CD8A
9 basal cell carcinoma 30.8 VDR TP63 TP53 TNF TLR7 PCNA
10 melanoma 30.8 TP53 TNF MKI67 MC1R IFNA1 CDKN2A
11 keratoacanthoma 30.8 TP63 TP53 MKI67 KRT10 FLG BCL2
12 telangiectasis 30.7 TP53 TNF H2AC18
13 epidermodysplasia verruciformis 1 30.7 TP53 CDKN2A CD8A
14 superficial basal cell carcinoma 30.7 TNF TLR8 TLR7 IFNA1 CD8A
15 porokeratosis 30.7 TP53 KRT10 FLG
16 leukoplakia 30.7 PCNA MKI67 FLG
17 exanthem 30.7 TNF IFNA1 H2AC18 CD8A
18 skin melanoma 30.6 TP53 MC1R KNSTRN H2AC18 CDKN2A
19 lichen planus 30.6 TP53 TNF KRT10 FLG
20 papilloma 30.6 TP63 TP53 PCNA KRT10 FLG CDKN2A
21 fungal infectious disease 30.5 TNF H2AC18 CD8A
22 vaginal cancer 30.5 TP53 CDKN2A CD8A
23 contact dermatitis 30.4 TNF FLG CD8A
24 common wart 30.4 TP53 TLR7 PCNA IFNA1
25 skin atrophy 30.4 TNF H2AC18 FLG
26 viral infectious disease 30.3 TNF TLR8 TLR7 IFNA1 H2AC18
27 human papillomavirus infectious disease 30.3 TP53 FLG CDKN2A CD8A
28 leprosy 3 30.3 VDR TNF CD8A
29 alopecia 30.3 VDR TP63 TNF FLG
30 melanoma in congenital melanocytic nevus 30.3 TP53 MKI67 MC1R H2AC18 CDKN2A
31 anogenital venereal wart 30.2 TP53 TNF TLR8 TLR7 IFNA1 H2AC18
32 vitiligo-associated multiple autoimmune disease susceptibility 1 30.2 TNF MC1R CD8A
33 lymphangioma 30.2 TP53 TNF H2AC18 CD8A BCL2
34 kidney cancer 30.2 TP53 IFNA1 H2AC18 CDKN2A
35 squamous cell carcinoma, head and neck 30.2 TP63 TP53 H2AC18 CDKN2A BCL2
36 esophageal cancer 30.1 TP53 TNF MKI67 H2AC18 CDKN2A CD8A
37 behcet syndrome 30.1 TNF IFNA1 H2AC18 CD8A
38 skin disease 30.0 VDR TP63 TP53 TNF TLR8 TLR7
39 myelodysplastic syndrome 29.9 TP53 TNF PCNA H2AC18 CDKN2A CD8A
40 leukemia, acute myeloid 29.8 TP53 TNF IFNA1 H2AC18 CDKN2A CD8A
41 leukemia, chronic lymphocytic 29.7 TP53 TNF TLR7 IFNA1 H2AC18 CDKN2A
42 renal cell carcinoma, nonpapillary 29.7 TP53 TNF MKI67 IFNA1 H2AC18 CDKN2A
43 systemic lupus erythematosus 29.7 TP53 TNF TLR8 TLR7 IFNA1 H2AC18
44 actinic cheilitis 11.2
45 basal cell carcinoma 1 11.0
46 fanconi anemia, complementation group e 10.8
47 early invasive cervical adenocarcinoma 10.4 CDKN2A BCL2
48 cystadenocarcinoma 10.4 TP53 PCNA BCL2
49 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.4 TP53 CDKN2A
50 endometrial squamous cell carcinoma 10.4 TP53 CDKN2A

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis

Symptoms & Phenotypes for Actinic Keratosis

MGI Mouse Phenotypes related to Actinic Keratosis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.18 BCL2 CD8A CDKN2A CYP27B1 GHR KNSTRN
2 neoplasm MP:0002006 10.15 BCL2 CDKN2A KRT10 MC1R MKI67 TLR7
3 renal/urinary system MP:0005367 10.11 BCL2 CD8A CYP27B1 GHR TLR7 TLR8
4 immune system MP:0005387 10.06 BCL2 CD8A CDKN2A CRLF3 CYP27B1 GHR
5 muscle MP:0005369 10.03 BCL2 CDKN2A GHR TLR7 TNF TP53
6 cellular MP:0005384 10.03 BCL2 CD8A CDKN2A CYP27B1 GHR KNSTRN
7 no phenotypic analysis MP:0003012 10.02 CDKN2A MC1R MKI67 PCNA TNF TP53
8 limbs/digits/tail MP:0005371 10.01 CYP27B1 GHR KRT10 MC1R TNF TP53
9 craniofacial MP:0005382 9.92 BCL2 CYP27B1 KRT10 MC1R TNF TP53
10 hematopoietic system MP:0005397 9.8 BCL2 CD8A CDKN2A CRLF3 CYP27B1 GHR
11 integument MP:0010771 9.36 BCL2 CD8A CDKN2A CYP27B1 GHR KRT10

Drugs & Therapeutics for Actinic Keratosis

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430
2
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
3
Prilocaine Approved Phase 4 721-50-6 4906
4
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
5
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
6
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
7
Tirbanibulin Approved, Investigational Phase 4 897016-82-9 23635314
8
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
9
Aminolevulinic acid Approved Phase 4 106-60-5 137
10
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
11
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
13 Radiation-Protective Agents Phase 4
14 Anti-Bacterial Agents Phase 4
15 Anti-Infective Agents Phase 4
16 Anti-Infective Agents, Local Phase 4
17 Protective Agents Phase 4
18 Anti-Arrhythmia Agents Phase 4
19 Sodium Channel Blockers Phase 4
20 Anesthetics, Local Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 Retinol palmitate Phase 4
23 Viscosupplements Phase 4
24 Methyl 5-aminolevulinate Phase 4
25 Dermatologic Agents Phase 4
26 Emollients Phase 4
27 Adjuvants, Immunologic Phase 4
28 interferons Phase 4
29 Immunologic Factors Phase 4
30 Pharmaceutical Solutions Phase 4
31
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
32
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
33
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
34
Selenium Approved, Investigational, Vet_approved Phase 3 7783-07-5, 7782-49-2 533
35
Selenious acid Approved, Investigational Phase 3 14124-67-5, 7783-00-8 1091
36 Keratolytic Agents Phase 3
37 Photosensitizing Agents Phase 3
38 Trace Elements Phase 3
39 Micronutrients Phase 3
40
Ethylene Phase 3 74-85-1 6325
41 Antifungal Agents Phase 3
42
Salicylates Phase 3
43 Antioxidants Phase 3
44
Sodium Selenite Phase 3
45 Sunscreening Agents Phase 3
46 Anesthetics Phase 3
47 Liver Extracts Phase 3
48
Digoxin Approved Phase 2 20830-75-5 3062 2724385 30322
49
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
50
Afamelanotide Approved, Investigational Phase 2 75921-69-6 16132954 16197727

Interventional clinical trials:

(show top 50) (show all 317)
# Name Status NCT ID Phase Drugs
1 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
2 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
3 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
4 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
5 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
6 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
7 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
8 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
9 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
10 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
11 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
12 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
13 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
14 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac
15 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
16 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
17 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
18 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
19 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
20 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Completed NCT02990221 Phase 4 Ingenol mebutate
21 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
22 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
23 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Completed NCT02984072 Phase 4 Menthol;Aqueous Cream
24 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
25 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
26 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
27 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
28 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
29 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
30 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
31 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
32 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
33 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
34 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
35 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Completed NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
36 Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial Completed NCT04875026 Phase 4 5-fluorouracil 4% (Tolak)
37 Clinical and Dermoscopic Evaluation of Long-pulsed 1064 nm Nd-YAG Laser Versus Trichloroacetic Acid 20% in Treatment of Keratosis Pilaris Completed NCT04797663 Phase 4 TCA 20%
38 Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream Completed NCT04842422 Phase 4 Imiquimod 3.75% Cream
39 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
40 A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp Recruiting NCT05387525 Phase 4 Tirbanibulin (Klisyri®) 10 mg/g ointment;Diclofenac Sodium 3% Gel
41 Safety and Efficacy of Photodynamic Therapy With Aminolevulinic Acid 10% Topical Gel Activated by Red Light Versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study Not yet recruiting NCT05359419 Phase 4
42 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Suspended NCT03963102 Phase 4 Ameluz
43 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
44 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
45 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
46 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
47 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
48 A Double-blind, Multicenter, Long-term Follow-up Study to Assess Recurrence of Actinic Keratosis in Subjects Treated With Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) or Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT), for Subjects Achieving Complete Response of Treated Lesions at Final Visit in Study RD.06.SPR.112199 Completed NCT04269395 Phase 3 MAL Cream;Vehicle cream
49 A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp Completed NCT03285490 Phase 3 KX2-391 Ointment 1%;Placebo
50 A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT Completed NCT02799082 Phase 3 Vehicle;BF-200 ALA

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Genetic Tests for Actinic Keratosis

Anatomical Context for Actinic Keratosis

Organs/tissues related to Actinic Keratosis:

MalaCards : Skin, Kidney, Liver, Eye, T Cells, Heart, Lung

Publications for Actinic Keratosis

Articles related to Actinic Keratosis:

(show top 50) (show all 2851)
# Title Authors PMID Year
1
[Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis]. 53 62
20098848 2009
2
The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. 53 62
19577853 2009
3
The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin. 53 62
16905862 2006
4
Noncalcemic actions of vitamin D receptor ligands. 53 62
15798098 2005
5
Expression profiles of p63, p53, survivin, and hTERT in skin tumors. 53 62
15268709 2004
6
Expression of p53, bcl-2 and growth hormone receptor in atrophic type of actinic keratosis. 53 62
14757281 2004
7
Human papillomavirus infection in actinic keratosis and bowen's disease: comparative study with expression of cell-cycle regulatory proteins p21(Waf1/Cip1), p53, PCNA, Ki-67, and Bcl-2 in positive and negative lesions. 53 62
14562284 2003
8
Expression of p53, bcl-2 and growth hormone receptor in actinic keratosis, hypertrophic type. 53 62
12756585 2003
9
Large cell acanthoma. 53 62
12581141 2003
10
Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. 53 62
10429981 1999
11
Expression of proliferating cell nuclear antigen (PCNA) and apoptosis related antigen (LeY) in epithelial skin tumors. 53 62
9557786 1998
12
Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. 53 62
9162299 1996
13
Relationship between actinic keratosis and malignant skin lesions on the eyelid. 62
35170648 2023
14
Photodynamic therapy with light emitting fabrics: a review. 62
34797414 2022
15
Treatment of actinic keratosis: a systematic review. 62
36454335 2022
16
Prevalence of 13 polyomaviruses in actinic keratosis and matched healthy skin samples of immunocompetent individuals. 62
36457033 2022
17
Keratinocyte Regnase-1, a down-regulator of skin inflammation, contributes to protection against tumor promotion by limiting COX-2 expression. 62
36470473 2022
18
Comparison of reflectance confocal microscopy and line-field optical coherence tomography for the identification of keratinocyte skin tumours. 62
36424847 2022
19
Predictors of subsequent primary melanoma: a case-control study. 62
34825952 2022
20
Hemodynamic changes during conventional and daylight photodynamic therapy of actinic keratoses - a randomized controlled trial. 62
35775704 2022
21
Measurements of illuminance in simulated daylight photodynamic therapy. 62
35437865 2022
22
Innovative digital solution supporting sun protection and vitamin D synthesis by using satellite-based monitoring of solar radiation. 62
35870076 2022
23
Cultural adaptation and validation of the quality of life questionnaire for patients with actinic keratosis (AKQoL-BR) to Brazilian Portuguese. 62
36137891 2022
24
Risk of squamous cell carcinoma in immunosuppressed patients with voriconazole-related actinic keratosis. 62
35986452 2022
25
Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a cross-sectional study. 62
35734826 2022
26
Comment on "Guidelines of care for the management of actinic keratosis". 62
35724889 2022
27
Efficacy of two different methods of cold air analgesia for pain relief in PDT of actinic keratoses of the head region - a randomized controlled comparison study. 62
36336323 2022
28
Potential use of microwave technology in dermatology. 62
35699665 2022
29
Reflectance confocal microscopy of facial neoplasms: Follicular involvement as a clue to diagnosis. 62
36321579 2022
30
Clinical Experience Using a Monofilament Fiber Cleansing and Debriding Technology for Various Skin Conditions. 62
36342736 2022
31
Fully home-based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study. 62
36184916 2022
32
Controlled register-based study of road traffic accidents in 12,651 Finnish cancer patients during 2013-2019. 62
36397273 2022
33
Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital Warts. 62
36362165 2022
34
Cutaneous Squamous Cell Carcinoma and Mortality in End-Stage Renal Disease. 62
36403674 2022
35
Risk of Skin Cancer and Actinic Keratosis in Patients with Rosacea: A Nationwide Population-based Cohort Study. 62
36250731 2022
36
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery. 62
35976634 2022
37
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. 62
36297594 2022
38
Demodicosis as a Skin Complication in Organ Transplant Recipients: A Case Series. 62
36206203 2022
39
The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A2 inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial. 62
36198452 2022
40
Commentary: Impact of Prior Treatment in the Efficacy and Tolerability of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies. 62
36408373 2022
41
Profile of Tirbanibulin for the Treatment of Actinic Keratosis. 62
36408375 2022
42
Commentary: Emotional and Social/Functioning Impact of Actinic Keratosis on Individuals Living with the Condition: An Exploratory Qualitative Research Initiative in the US. 62
36408374 2022
43
Pigmented Actinic Keratosis Versus In Situ Melanoma: PRAME May Be Helpful. 62
35925568 2022
44
Influence of serum vitamin D level in the response of actinic keratosis to ingenol mebutate. 62
36261393 2022
45
Commentary: Complete Clearance of Actinic Keratosis with Tirbanibulin Ointment 1% is not Correlated with the Severity of Local Skin Reactions. 62
36408376 2022
46
Skin Microbiome Variation with Cancer Progression in Human Cutaneous Squamous Cell Carcinoma. 62
35390349 2022
47
Clinical Characteristics of Actinic Keratosis Associated with the Risk of Progression to Invasive Squamous Cell Carcinoma: A Systematic Review. 62
36233766 2022
48
Characteristics and management of skin cancers in very elderly patients: A real-world challenge for clinicians. 62
35723894 2022
49
MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin. 62
34647185 2022
50
A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid. 62
35661760 2022

Variations for Actinic Keratosis

Expression for Actinic Keratosis

Search GEO for disease gene expression data for Actinic Keratosis.

Pathways for Actinic Keratosis

Pathways related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 TP53 TNF TLR8 TLR7 PCNA IFNA1
2
Show member pathways
12.41 TNF TLR8 TLR7 IFNA1
3 12.39 TNF TLR8 TLR7 IFNA1 CD8A
4 12.27 TP63 TP53 PCNA MKI67 CDKN2A
5
Show member pathways
12.13 BCL2 CDKN2A TP53 TP63
6 12.05 TP53 TNF TLR8 TLR7
7
Show member pathways
11.99 TP53 TNF CDKN2A CD8A
8 11.69 TP53 PCNA CDKN2A BCL2
9 11.65 TNF TLR7 CD8A
10 11.64 TP63 TP53 CDKN2A
11 11.56 TNF TLR8 TLR7
12 11.5 BCL2 FLG TNF TP53
13 11.48 VDR TP63 CDKN2A
14 11.46 VDR TP63 TP53 PCNA BCL2
15 11.44 VDR TNF CYP27B1
16 11.4 VDR TP63 CDKN2A
17 11.35 VDR TNF CYP27B1
18 11.27 BCL2 PCNA TNF
19 11.19 TP53 TNF BCL2
20 11.14 VDR CYP27B1 BCL2
21 10.62 VDR CYP27B1
22 10.62 TLR8 TLR7
23 10.58 VDR TNF BCL2
24 10.36 TP53 BCL2
25
Show member pathways
10.23 TP63 TP53 CDKN2A BCL2

GO Terms for Actinic Keratosis

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.02 BCL2 CDKN2A CYP27B1 TNF TP53 VDR
2 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.85 TNF GHR CRLF3
3 positive regulation of vitamin D receptor signaling pathway GO:0070564 9.76 VDR CYP27B1
4 B cell lineage commitment GO:0002326 9.71 TP53 BCL2
5 T cell lineage commitment GO:0002360 9.61 TP53 BCL2
6 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.56 VDR CYP27B1
7 negative regulation of mitotic cell cycle GO:0045930 9.46 TP53 TNF BCL2
8 negative regulation of cell growth GO:0030308 9.32 TP53 CYP27B1 CRLF3 CDKN2A BCL2
9 response to external stimulus GO:0009605 9.13 TLR8 TLR7 BCL2

Sources for Actinic Keratosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....